Monday, January 24, 2022
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina

NEWS

NEWS

First injectable drug to prevent HIV approved

first-injectable-drug-to-prevent-hiv-approved

First injectable drug to prevent HIV approved

Washington, Dec 23 (Prensa Latina) The first injectable drug to prevent HIV has been approved by the United States Food and Drug Administration (FDA).
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

Apretude, as the drug is called, has a long-lasting effect and must be administered every two months, the regulatory entity points out.

It will serve “to prevent infection by the human immunodeficiency virus (HIV) in adults and adolescents at risk who have tested negative just before starting treatment and whose body mass exceeds 35 kilograms”, underlines the source.

The safety and efficacy of Apretude were evaluated in two trials.

One of them included 4,566 cisgender men (people whose gender identity and expression matches their biological sex assigned to them when they were born), and transgender women who have sex with men.

Side effects of Apretude include local skin reactions, fatigue, fever, headaches, muscle and back pain, and inflammation of the skin.

The US Food and Drug Administration endorsed the injection, but noted a series of precautions related to hypersensitivity reactions, hepatotoxicity (liver damage) and depressive disorders.

HIV is a lentivirus, a genus of the retrovirus family, which causes the development of Acquired Immune Deficiency Syndrome (AIDS).

That disease progresses to immune system failure, allowing opportunistic infections and life-threatening cancers to develop.

ef/acl/joe

ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.